The Janssen Pharmaceutical Companies of Johnson & Johnson launched VISIBLE, a phase 3b study with a focus on plaque and scalp psoriasis in people of color, according to a press release.
Approximately 200 participants in the U.S. and Canada who self-identify as non-white will be included in the double-blind, randomized, placebo-controlled study evaluating safety and efficacy of Tremfya (guselkumab) as a treatment for either or both moderate to severe plaque psoriasis and moderate to severe scalp psoriasis in this population.
«There are racial and ethnic variations in the prevalence,